CAR T-cell therapy has revolutionized the treatment of blood cancers like leukemia and lymphoma. However, its effectiveness against solid tumors has remained limited. This challenge arises from the heterogeneous nature of solid tumors, which often lack a uniform target on their surface. Moreover, these tumors frequently reside within a protective barrier formed by dense scar tissue and immune-suppressive cells that hinder T-cell activity.
The Innovative Approach
Researchers at Memorial Sloan Kettering Cancer Center have made significant strides to overcome these hurdles by developing a novel CAR T-cell that specifically targets a surface protein known as the urokinase plasminogen activator receptor (uPAR). Their recent study, published in a prominent scientific journal, outlines how this innovative strategy targets the supportive cells within the tumor microenvironment that express uPAR.
The findings reveal that uPAR is markedly elevated in 12 out of 14 human cancer types analyzed. Its heightened expression correlates strongly with mutations that compromise the p53 tumor-suppressor gene, often referred to as the ‘guardian of the genome.’ Additionally, activating mutations in KRAS and other genes within the RAS signaling pathway also show a strong association with increased uPAR levels. The study further indicates that elevated uPAR is linked to the activation of genes associated with cellular plasticity, inflammation, and fibrosis—key characteristics of aggressive tumors.
Promising Experimental Outcomes
Scott Lowe, PhD, who leads the cancer biology and genetics program at MSK and is a co-corresponding author of the research, noted the potential of this uPAR-targeting approach. In laboratory settings, the engineered CAR T-cells successfully reduced the size of various solid tumors, including lung, pancreatic, and ovarian cancers. Remarkably, in some experiments, these cells even eradicated metastases, showcasing their powerful action against tumor cells and the supportive fibroblasts and myeloid cells that facilitate tumor growth.
The research team rigorously tested the efficacy of the uPAR-targeted CAR T-cells across multiple preclinical models, including human tumors implanted in mice and models mimicking metastatic disease. They discovered that the therapeutic effects were significantly enhanced when these CAR T-cells were combined with senescence-inducing treatments, such as the chemotherapy drug cisplatin.
Lasting Impact in Ovarian Cancer Models
In a specific mouse model of ovarian cancer, the uPAR-targeting CAR T-cells led to durable remissions. Remarkably, the mice that had their tumors eliminated demonstrated resistance to new tumor development, indicating that the CAR T-cells remained active even after initial treatment. Furthermore, a single dose of these engineered cells administered post-surgery effectively eliminated residual disease, outperforming surgery alone, which only provided temporary relief.
This novel targeting strategy emphasizes the ability to focus on cells in a specific functional state, rather than merely targeting cell types. The study supports earlier findings from MSK that even when such cells represent a minor subpopulation within the tumor, their elimination can trigger a collapse of the tumor structure, underscoring the significance of these specialized cell states.
Expanding Therapeutic Horizons
The implications of targeting uPAR extend beyond CAR T-cells. Researchers are exploring other therapeutic modalities, including antibody-drug conjugates (ADCs), antibody-directed radiation, and CAR-based natural killer cell therapies. Additionally, the research team has identified two promising methods to monitor uPAR-high disease without invasive biopsies. They suggest measuring suPAR, a soluble fragment of uPAR, in the bloodstream, and employing uPAR-targeted PET scans to visualize tumors and metastases, as well as to track responses to treatment over time.
Future Directions for CAR T-Cell Therapy
As CAR T-cell therapy continues to evolve, targeting uPAR opens new avenues for effectively treating solid tumors. This innovative approach not only enhances the therapeutic arsenal against cancer but also provides a framework for understanding the tumor microenvironment’s complexity.
In summary, the breakthrough research from Memorial Sloan Kettering Cancer Center represents a significant leap forward in cancer therapy. By focusing on uPAR, scientists have identified a viable strategy to tackle solid tumors, potentially transforming the landscape of cancer treatment.
Key Takeaways
- CAR T-cell therapy has shown limited success against solid tumors due to their heterogeneous nature and protective microenvironments.
- Researchers have developed a CAR T-cell that targets the uPAR protein, present in multiple cancer types, enhancing the therapy’s effectiveness.
-
Preclinical studies demonstrated that uPAR-targeting CAR T-cells could shrink solid tumors and eliminate metastases, particularly when combined with chemotherapy.
-
This approach highlights the potential to target specific cellular states rather than relying solely on distinguishing cell types.
-
Monitoring techniques for uPAR-high disease without biopsies could revolutionize cancer tracking and treatment response evaluation.
In conclusion, the advancements in targeting uPAR with CAR T-cell therapy not only pave the way for more effective solid tumor treatments but also invite further exploration into the intricate dynamics of tumor biology. The future of cancer therapy looks promising as researchers continue to innovate and refine these groundbreaking strategies.
Read more → www.genengnews.com